nanobiotix

Paris, France, February 2^nd 2011 – NANOBIOTIX the leading nanomedecine company focused on cancer therapy, announced today that its team has completed a comprehensive executive research and appointed Bernd Mühlenweg, PhD, as Head of Business Development.
Based on his comprehensive experience Dr Mühlenweg will be responsible for ensuring sustainable corporate growth by establishing strategic corporate and business alliances.

Dr Laurent Levy, CEO and co-founder of the company says: “This is a pivotal time for Nanobiotix: we are confident that Bernd’s specific skills in license agreements, alliance management, development and commercialisation, will reinforce Nanobiotix’ leading role in the nanomedecine field. This partnership is intented to mark a major step towards realisation of most promising nanomedecine agenda for pharma industry.”

Dr. Mühlenweg comments: “Nanobiotix has developed a truly unique pipeline of products to address the various applications of radiotherapy in different types of cancer. I look forward to helping this talented team in the crucial next phase of the company’s growth. My goal is to make NanoXray^TM technology a first-in-class approach in oncology and to make it the physician’s choice for personalized and efficacious cancer treatment with low side effects”.

Dr Mühlenweg, 39, holds a PhD in Chemistry from the Technical University of Munich. He completed his education with a Leadership program at St. Galler Business School and several M&A and negotiation workshops. He was involved in the negotiation and execution of several license and commercialization agreements and has almost 10 years experience in the pharmaceutical business development field. Dr Mühlenweg is co-author of numerous publications and 2 patents. He is a member of the Pharma Licensing Club of Germany (Pharmalizenzclub) and of the Protection Rights and Technical Contracts Committee of BioDeutschland. Most recently, Bernd served as Director Business Development of Munich based WILEX AG where he contributed significantly to acheiving WILEX leadership position in developing cancer therapeutics and diagnostics.